

Press release
Lund 23 Jan 2023

TSE treatments at the Royal Veterinary College shows very promising results

Scandinavian ChemoTech's fully owned subsidiary Vetiqure receives very promising updates from the veterinarians at the Royal Veterinary College (RVC) who are now ready to start actively recommending the TSE treatment.

The first horse in question suffers from a severe sarcoid on the hoof which has previously been had surgery and several treatments with an older static electroporation device without positive/satisfying results. We are now receiving continuous encouraging progress updates, reported to RVC by the horses' owner, who last stated: *"Looking much better today, particularly after being exposed to the air for a few hours. It's contracting and melting back; less prominent visually."*

Even if the TSE treatment has previously shown to give complete remission of sarcoids, this is the first time a horse has been treated after static electrochemotherapy (ECT) has failed and with only sedation and local anaesthesia.

The second horse suffers from a large sarcoid on the cheek. The latest update that RVC received from the owners stated: *"Just another update for you – the sarcoid is continuing to shrink"*.

According to the responsible veterinarian for Ted it is difficult to even appreciate where the sarcoid is now, which is very positive news. You can just make out the white dots on the skin over the area where the sarcoid had been treated.

RVC announces that they will be set to start actively recommending the TSE treatment within a few weeks after witnessing these results.

"We are very happy that veterinarians in both Europe and USA are confirming that TSE is not causing the same side-effects as the devices with the older ECT does. Though the clinical results are very encouraging, the true game changer is that TSEs softer dynamic pulse makes it possible to treat horses without general anaesthesia, which is both expensive and can be directly life-threatening to them." – says Mohan Frick CEO and co-founder of Scandinavian ChemoTech

Facts:

About 2 % of horses develop sarcoids* and it is estimated that there are about 6 million horses in the EU alone*. If the clinical results from the evaluations continue to show these results on sarcoid in horses, this can become a major market segment where TSE seems to have a competitive advantage.

*1 <https://thehorse.com/169559/facts-about-sarcoids-in-horses/>

*2 https://food.ec.europa.eu/animals/live-animal-movements/equine-animals_en

Pictures of both horses will be published on the Instagram page:
<https://www.instagram.com/tse.veterinary/>

For further information please contact:
Mohan Frick, CEO

Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.